Cargando…
Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies
BACKGROUND: Serum interleukin (IL)-6 has been found to be associated with sleep quality, mood, and survival in patients with solid tumors. Results in these studies were confounded by knowledge of diagnosis to study subjects. Moreover, such data among subjects with hematological malignancies and data...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338000/ https://www.ncbi.nlm.nih.gov/pubmed/30765978 http://dx.doi.org/10.4103/jnrp.jnrp_159_18 |
_version_ | 1783388380673867776 |
---|---|
author | Chandra, Smita Gupta, Vibha Chandra, Harish Dhyani, Mohan Kotwal, Aarti Verma, Sanjiv Kumar Gupta, Ravi |
author_facet | Chandra, Smita Gupta, Vibha Chandra, Harish Dhyani, Mohan Kotwal, Aarti Verma, Sanjiv Kumar Gupta, Ravi |
author_sort | Chandra, Smita |
collection | PubMed |
description | BACKGROUND: Serum interleukin (IL)-6 has been found to be associated with sleep quality, mood, and survival in patients with solid tumors. Results in these studies were confounded by knowledge of diagnosis to study subjects. Moreover, such data among subjects with hematological malignancies and data regarding restless legs syndrome is limited. The present study was, therefore, conducted to assess the sleep quality, depression, and restless leg syndrome in hematological malignancies and to study if there is any role of IL6 associated with it. METHODS: Sixty-six subjects having hematological malignancy were included in this study after excluding the potential confounders. Sleep quality was examined using Pittsburg Sleep Quality Index, depression by the Patient Health Questionnaire-9. Diagnosis of RLS was made through clinical examination. Serum for measurement of IL-6 was collected at baseline and after 1 month of initiation of chemotherapy. Patients were followed up for 6 months. RESULTS: Average age of study subjects was 50.16 years with male predominance. Nearly 22.7% had clinical depression, 28.8% had poor quality sleep, and restless legs syndrome (RLS) was reported in 6.1% cases. Nearly 22.7% patients died at 6 months. Disturbed sleep at baseline was associated with depression (odds ratio [OR] =7.89) and poor 6 months survival. Serum IL-6 did not show any association with sleep quality, restless-legs-syndrome, and depression. However, baseline high level of serum IL-6 (OR = 26.06) and low level after chemotherapy (OR = 0.03) were associated with poor survival at 6 months. CONCLUSION: Poor quality sleep, depression, and RLS are prevalent among adult subjects with hematological malignancies. Sleep disturbance, high pretreatment inflammatory and lowering of inflammatory load after chemotherapy increase likelihood for poor prognosis. Serum IL-6 did not show any association with sleep quality, restless legs syndrome and depression. |
format | Online Article Text |
id | pubmed-6338000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63380002019-02-14 Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies Chandra, Smita Gupta, Vibha Chandra, Harish Dhyani, Mohan Kotwal, Aarti Verma, Sanjiv Kumar Gupta, Ravi J Neurosci Rural Pract Original Article BACKGROUND: Serum interleukin (IL)-6 has been found to be associated with sleep quality, mood, and survival in patients with solid tumors. Results in these studies were confounded by knowledge of diagnosis to study subjects. Moreover, such data among subjects with hematological malignancies and data regarding restless legs syndrome is limited. The present study was, therefore, conducted to assess the sleep quality, depression, and restless leg syndrome in hematological malignancies and to study if there is any role of IL6 associated with it. METHODS: Sixty-six subjects having hematological malignancy were included in this study after excluding the potential confounders. Sleep quality was examined using Pittsburg Sleep Quality Index, depression by the Patient Health Questionnaire-9. Diagnosis of RLS was made through clinical examination. Serum for measurement of IL-6 was collected at baseline and after 1 month of initiation of chemotherapy. Patients were followed up for 6 months. RESULTS: Average age of study subjects was 50.16 years with male predominance. Nearly 22.7% had clinical depression, 28.8% had poor quality sleep, and restless legs syndrome (RLS) was reported in 6.1% cases. Nearly 22.7% patients died at 6 months. Disturbed sleep at baseline was associated with depression (odds ratio [OR] =7.89) and poor 6 months survival. Serum IL-6 did not show any association with sleep quality, restless-legs-syndrome, and depression. However, baseline high level of serum IL-6 (OR = 26.06) and low level after chemotherapy (OR = 0.03) were associated with poor survival at 6 months. CONCLUSION: Poor quality sleep, depression, and RLS are prevalent among adult subjects with hematological malignancies. Sleep disturbance, high pretreatment inflammatory and lowering of inflammatory load after chemotherapy increase likelihood for poor prognosis. Serum IL-6 did not show any association with sleep quality, restless legs syndrome and depression. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6338000/ /pubmed/30765978 http://dx.doi.org/10.4103/jnrp.jnrp_159_18 Text en Copyright: © 2019 Journal of Neurosciences in Rural Practice http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Chandra, Smita Gupta, Vibha Chandra, Harish Dhyani, Mohan Kotwal, Aarti Verma, Sanjiv Kumar Gupta, Ravi Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies |
title | Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies |
title_full | Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies |
title_fullStr | Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies |
title_full_unstemmed | Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies |
title_short | Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies |
title_sort | serum interleukin-6 is not linked with sleep-quality, restless legs syndrome, and depression, but with 6-month survival in hematological malignancies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338000/ https://www.ncbi.nlm.nih.gov/pubmed/30765978 http://dx.doi.org/10.4103/jnrp.jnrp_159_18 |
work_keys_str_mv | AT chandrasmita seruminterleukin6isnotlinkedwithsleepqualityrestlesslegssyndromeanddepressionbutwith6monthsurvivalinhematologicalmalignancies AT guptavibha seruminterleukin6isnotlinkedwithsleepqualityrestlesslegssyndromeanddepressionbutwith6monthsurvivalinhematologicalmalignancies AT chandraharish seruminterleukin6isnotlinkedwithsleepqualityrestlesslegssyndromeanddepressionbutwith6monthsurvivalinhematologicalmalignancies AT dhyanimohan seruminterleukin6isnotlinkedwithsleepqualityrestlesslegssyndromeanddepressionbutwith6monthsurvivalinhematologicalmalignancies AT kotwalaarti seruminterleukin6isnotlinkedwithsleepqualityrestlesslegssyndromeanddepressionbutwith6monthsurvivalinhematologicalmalignancies AT vermasanjivkumar seruminterleukin6isnotlinkedwithsleepqualityrestlesslegssyndromeanddepressionbutwith6monthsurvivalinhematologicalmalignancies AT guptaravi seruminterleukin6isnotlinkedwithsleepqualityrestlesslegssyndromeanddepressionbutwith6monthsurvivalinhematologicalmalignancies |